Results 11 to 20 of about 70,002 (313)
New England Journal of Medicine, 2021 Background and Objectives Discoveries of dermatomyositis-specific antibodies (DMSAs) in patients with dermatomyositis raised awareness of various myopathologic features among antibody subtypes.
J. Tanboon +8 more
semanticscholar +5 more sources
, 2008 Dermatomyositis (DM) is a chronic inflammatory disorder of the skin and muscles. Although thought to be autoimmune in origin, many questions remain as to the etiopathogenesis of this disease. DM has classically been considered a humorally mediated disease.
M S, Krathen, D, Fiorentino, V P, Werth
core +8 more sources
Dermatomyositis: Practical Guidance and Unmet Needs
ImmunoTargets and TherapyLydia Cassard,1 Noelle Seraly,2 Maureen Riegert,3 Aditi Patel,4 Anthony P Fernandez5 1Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA; 2Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA ...
Cassard L +4 more
doaj +2 more sources
Narrowband Intense Pulsed Light Treatment for Refractory Facial Rash Associated with Dermatomyositis
Clinical, Cosmetic and Investigational Dermatology, 2023 Yuxin Zheng, Suiqing Cai Department of Dermatology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, People’s Republic of ChinaCorrespondence: Suiqing Cai, Department of Dermatology, Zhejiang University School of Medicine ...
Zheng Y, Cai S
doaj +3 more sources
Paraneoplastic dermatomyositis with Kaposi's sarcoma: A case report. [PDF]
SAGE Open Med Case RepDermatomyositis is a rare autoimmune condition known to be frequently associated with an undiagnosed malignancy. Although it is strongly linked to adenocarcinomas and other solid tumors, dermatomyositis has been scarcely described with sarcomas.
Qian SY, Qin K, Desrochers J.
europepmc +2 more sources
Respirology Case Reports, 2021 We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and ...
Ryosuke Imai +2 more
doaj +2 more sources
Acta Dermato-Venereologica, 2018 Anti-transcriptional intermediary factor-1γ (TIF-1γ) autoantibody may be associated with cancer in adult patients with dermatomyositis. The aim of this study was to evaluate the risk of cancer in the presence of anti-TIF-1γ autoantibody in adult ...
Marion Best +5 more
doaj +2 more sources
Trigeminal involvement in dermatomyositis with double positivity for anti-transcriptional intermediary factor 1 gamma and anti-Ku antibodies: A case report and literature review. [PDF]
J Int Med ResAnti-transcriptional intermediary factor 1 gamma antibody and anti-Ku antibody double-positive dermatomyositis and trigeminal neuropathy involvement are often regarded as clinically distinct diseases with differing pathogenesis. Herein, we present a rare
Yingchao S +5 more
europepmc +2 more sources
JID InnovationsThe Total Improvement Score (TIS), which is used as the primary efficacy measure in dermatomyositis (DM) clinical trials, lacks a skin-specific measure. However, skin is a defining feature of DM.
Rachita Pandya +5 more
doaj +2 more sources
Pneumomediastinum and Pneumopericardium in Rapidly Progressive Interstitial Lung Disease Secondary to Anti-MDA5 Dermatomyositis. [PDF]
Clin Case RepAnti‐melanoma differentiation associated protein 5 antibody positive dermatomyositis (anti‐MDA5 dermatomyositis) is characterized by rapidly progressive interstitial lung disease and skin involvement with a paucity of muscle involvement.
Bond T +3 more
europepmc +2 more sources